Research topics of the group

Migrastatics

Metastasis accounts for more than 90% of cancer-related deaths. Despite recent advances in cancer therapies, the majority of patients with advanced-stage solid tumors die as a result of metastatic disease. Migrastatics represent a new concept of drugs with a great potential to improve the outcome of the current cancer treatment strategies by inhibiting metastatic behavior of cancer cells.

Our goal is to use rational design to synthesize new natural compound analogs with antimetastatic activity. We study structure-activity relationships. Our protein target is actin and actin polymerization regulators, such as the Arp2/3 complex. Antimetastatic activity screening of the new compounds is performed in collaboration with Prof. Jan Brábek group at BIOCEV (Vestec).

Projects:

2023-2027:      Development of actin polymerization inhibitors as potential migrastatics (GAČR)

2021-2022:      Development of actin-targeting compounds with anti-metastatic effect (Dagmar Procházková Fund)

Antiparasitic compounds

Trypanosomatids are causative agents of several diseases transmitted by insects: Chagas disease (Trypanosoma cruzi), human african trypanosomiasis known as „sleeping sickness“ (Trypanosoma b. gambiense, Trypanosoma b. rhodesiense) and leischmaniasis (Leischmania sp.). The current treatment of these diseases is complicated. Therefore, we study natural compounds, elucidate their mechanism of action and synthesize their analogs for further development as potential drugs. New compounds are developed in collaboration with the group of Prof. Vyacheslav Yurchenko (University of Ostrava).